Source: Virtual Congress 2020 – Genetics and genomics of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Legchenko (Cambridge, United Kingdom), B. Liu (Cambridge, United Kingdom), J. West (Cambridge, United Kingdom), P. Vangheluwe (Leuven, Belgium), P. Upton (Cambridge, United Kingdom), N. Morrell (Cambridge, United Kingdom). Protein truncating mutations in ATP13A3 promote pulmonary arterial hypertension. 4463

Member's Comments

No comment yet.

Related content which might interest you: Screening of pulmonary arterial hypertension in BMPR2 mutation carriers Source: Virtual Congress 2020 – Genetics and genomics of pulmonary arterial hypertension Year: 2020 Clinical manifestation of hereditary pulmonary arterial hypertension by a ²second hit² mutation in the genes BMPR2 and EIF2AK4 Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Relationship of BMPR2 mutations and vasoreactivity in pulmonary arterial hypertension Source: Research Seminar 2005 - Pulmonary Circulation: Molecular Determinants of Pulmonary Vascular Remodelling Year: 2005 Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension Source: Eur Respir J 2014; 43: 1195-1198 Year: 2014 Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation Source: Eur Respir J, 55 (5) 1902340; 10.1183/13993003.02340-2019 Year: 2020 BMPR2 mutations and iron metabolism in pulmonary arterial hypertension patients Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021 T-box protein 4 mutation causing pulmonary arterial hypertension and lung disease Source: Eur Respir J, 54 (2) 1900388; 10.1183/13993003.00388-2019 Year: 2019 Clinical characteristics, hemodynamics and survival in idiopathic and familial pulmonary arterial hypertension with germline BMPR2 mutation Source: Eur Respir J 2007; 30: Suppl. 51, 250s Year: 2007 Familial pulmonary arterial hypertension by KDR heterozygous loss of function Source: Eur Respir J, 55 (4) 1902165; 10.1183/13993003.02165-2019 Year: 2020 Molecular analysis of genes BMPR2 and KCNA5 in Spanish patients with pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models Year: 2012 Pulmonary arterial hypertension associated with several mutations Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1668-1681 Year: 2016 Functional characterization of BMPR2 gene in pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Echocardiography of pulmonary vascular function in asymptomatic carriers of BMPR2 mutations Source: Eur Respir J 2012; 40: 1287-1289 Year: 2012 Analysis of the subcellular localization in BMPR2 gene in pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Endoglin germline mutation, hereditary hemorrhagic telangiectasia and fenfluramine-associated pulmonary arterial hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003 Functional analysis of the 5´UTR region of BMPR2 gene in pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis Source: Eur Respir J 2015; 46: 474-485 Year: 2015 Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation Source: Eur Respir J 2012; 39: 1534-1535 Year: 2012 Pulmonary arterial hypertension preceding idiopathic pulmonary fibrosis in a BMPR2 mutation positive patient Source: Eur Respir Rev 2014; 23: 147-149 Year: 2014